MedTrace Logo

Effect of Arginine Supplementation in the Metabolic Syndrome

NCT02354794 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-02-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether oral supplementation with one form of arginine improves vascular endothelial function in healthy subjects with risk factors associated with the metabolic syndrome

Conditions

Interventions

DIETARY_SUPPLEMENT

One form of arginine

3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month

DIETARY_SUPPLEMENT

placebo

3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month

Sponsors & Collaborators

  • Institut de Recherche Pierre Fabre

    collaborator OTHER

  • Hospital Avicenne

    collaborator OTHER

  • Adeprina

    collaborator OTHER

  • Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement

    lead OTHER

Principal Investigators

  • Robert Benamouzig · Hospital Avicenne

  • François Mariotti, PhD · AgroParisTech

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-05-31
Completion
2014-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02354794 on ClinicalTrials.gov